Last10K.com

La Jolla Pharmaceutical Co (LJPC) SEC Filing 10-Q Quarterly Report for the period ending Thursday, September 30, 2021

La Jolla Pharmaceutical Co

CIK: 920465 Ticker: LJPC
Document and Entity Information - shares
9 Months Ended
Sep. 30, 2021
Oct. 22, 2021
Cover [Abstract]  
Document Type10-Q 
Document Quarterly Reporttrue 
Document Transition Reportfalse 
Entity File Number1-36282 
Entity Registrant NameLA JOLLA PHARMACEUTICAL COMPANY 
Entity Incorporation, State or Country CodeDE 
Entity Tax Identification Number33-0361285 
Entity Address, Address Line One201 Jones Road 
Entity Address, Address Line TwoSuite 400 
Entity Address, City or TownWaltham 
Entity Address, State or ProvinceMA 
Entity Address, Postal Zip Code02451 
City Area Code617 
Local Phone Number715-3600 
Title of 12(b) SecurityCommon Stock, par value $0.0001 per share 
Trading SymbolLJPC 
Security Exchange NameNASDAQ 
Current Reporting StatusYes 
Entity Interactive Data CurrentYes 
Entity Filer CategoryNon-accelerated Filer 
Entity Small Businesstrue 
Entity Emerging Growth Companyfalse 
Shell Companyfalse 
Entity Common Stock, Shares Outstanding 27,524,028
Entity Central Index Key0000920465 
Document Period End DateSep. 30, 2021 
Amendment Flagfalse 
Document Fiscal Year Focus2021 
Document Fiscal Period FocusQ3 
Current Fiscal Year End Date--12-31 

View differences made from one quarter to another to evaluate La Jolla Pharmaceutical Co's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by La Jolla Pharmaceutical Co.

Continue

Assess how La Jolla Pharmaceutical Co's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

La Jolla Pharmaceutical Co's Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Rating

Learn More
Bullish Bearish Neutral
Filter by Sentiment:
All
Positive
Negative
Filter by Category:
All
Revenue
Financial
M & A
Other
Filter by Subcategory:
All
Product
Expense
Other
Inside La Jolla Pharmaceutical Co's 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parenthetical)
Condensed Consolidated Statements Of Cash Flows (Unaudited)
Condensed Consolidated Statements Of Operations (Unaudited)
Condensed Consolidated Statements Of Shareholders' Deficit (Unaudited)
Acquisition Of Tetraphase Pharmaceuticals, Inc
Acquisition Of Tetraphase Pharmaceuticals, Inc (Tables)
Acquisition Of Tetraphase Pharmaceuticals, Inc - Summary Of Purchase Price Allocation As Of Acquisition Date (Details)
Acquisition Of Tetraphase Pharmaceuticals, Inc. Additional Information (Details)
Balance Sheet Details
Balance Sheet Details (Tables)
Balance Sheet Details - Additional Information (Details)
Balance Sheet Details - Property Plant And Equipment (Details)
Balance Sheet Details - Schedule Of Intangible Assets, Net (Details)
Balance Sheet Details - Schedule Of Inventory (Details)
Balance Sheet Details - Schedule Of Other Noncurrent Liabilities (Details)
Balance Sheet Details - Schedule Of Prepaid Expenses And Other Current Assets (Details)
Balance Sheet Details - Summary Of Accrued Expenses (Details)
Basis Of Presentation And Summary Of Significant Accounting Policies
Basis Of Presentation And Summary Of Significant Accounting Policies (Policies)
Basis Of Presentation And Summary Of Significant Accounting Policies (Tables)
Basis Of Presentation And Summary Of Significant Accounting Policies - Additional Information (Details)
Basis Of Presentation And Summary Of Significant Accounting Policies - Schedule Of Concentration Risk (Details)
Business
Business - Additional Information (Details)
Commitments And Contingencies
Commitments And Contingencies (Tables)
Commitments And Contingencies - Additional Information (Details)
Commitments And Contingencies - Future Minimum Lease Payments Excluding Operating Costs (Details)
Company-Wide Realignment
Company-Wide Realignments - Additional Information (Details)
Deferred Royalty Obligation
Deferred Royalty Obligation - Additional Information (Details)
Earnings (Loss) Per Share
Earnings (Loss) Per Share - Additional Information (Details)
Equity Incentive Plans
Equity Incentive Plans (Tables)
Equity Incentive Plans - Narrative (Details)
Equity Incentive Plans - Share-Based Compensation Expense (Details)
Equity Incentive Plans - Stock Option Activity (Details)
Equity Incentive Plans - Stock Option Activity (Parenthetical) (Details)
Income Taxes
Income Taxes - Additional Information (Details)
License Agreements
License Agreements - Additional Information (Details)
Other Income-Related Party
Other Income-Related Party - Additional Information (Details)
Shareholders Equity
Shareholders' Equity - Additional Information (Details)
Subsequent Event

Material Contracts, Statements, Certifications & more

La Jolla Pharmaceutical Co provided additional information to their SEC Filing as exhibits

Ticker: LJPC
CIK: 920465
Form Type: 10-Q Quarterly Report
Accession Number: 0001564590-21-054269
Submitted to the SEC: Thu Nov 04 2021 8:31:19 AM EST
Accepted by the SEC: Thu Nov 04 2021
Period: Thursday, September 30, 2021
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/ljpc/0001564590-21-054269.htm